祖先株与B.1.351株AS03佐剂重组植物源病毒样颗粒疫苗诱导对SARS-CoV-2变异株的广谱中和
在小鼠中评估了加拿大卫生当局近期批准的祖先株COVID-19重组植物源病毒样颗粒疫苗(CoVLP)与靶向B.1.351变异株的改良CoVLP.B1351(均含AS03佐剂)的同源与异源初免-加强方案,两种策略均诱导针对多个关切变异株的强而广谱交叉反应中和抗体应答,异源初免-加强后对几乎所有关切变异株的中和抗体应答趋于更高。
要点
- 祖先株CoVLP与B.1.351株CoVLP.B1351(均含AS03佐剂)在小鼠中评估同源与异源初免-加强方案。
- 两种初免策略均诱导针对B.1.351/Beta、B.1.1.7/Alpha、P.1/Gamma、B.1.617.2/Delta和B.1.1.529/Omicron的强而广谱交叉反应中和抗体应答。
- 异源初免-加强后对几乎所有关切变异株的中和抗体应答趋于更高。
核心结论
- 祖先株CoVLP与CoVLP.B1351的同源和异源初免-加强方案在小鼠中均诱导强而广谱的针对多个关切变异株的交叉反应中和抗体应答,异源初免-加强后对几乎所有关切变异株的中和抗体应答趋于更高。
研究设计与样本
- 在小鼠中评估祖先株COVID-19重组植物源病毒样颗粒疫苗(CoVLP)与靶向B.1.351变异株的改良CoVLP.B1351(均含AS03佐剂)的同源与异源初免-加强方案。
主要发现
- 两种初免策略均诱导针对B.1.351/Beta、B.1.1.7/Alpha、P.1/Gamma、B.1.617.2/Delta和B.1.1.529/Omicron变异株的强而广谱交叉反应中和抗体应答。
- 异源初免-加强后对几乎所有关切变异株的中和抗体应答趋于更高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection resulting in the coronavirus disease 2019 (COVID-19) has afflicted hundreds of millions of people in a worldwide pandemic. Several safe and effective COVID-19 vaccines are now available. However, the rapid emergence of variants and risk of viral escape from vaccine-induced immunity emphasize the need to develop broadly protective vaccines. A recombinant plant-derived virus-like particle vaccine for the ancestral COVID-19 (CoVLP) recently authorized by Canadian Health Authorities and a modified CoVLP.B1351 targeting the B.1.351 variant (both formulated with the adjuvant AS03) were assessed in homologous and heterologous prime-boost regimen in mice. Both strategies induced strong and broadly cross-reactive neutralizing antibody (NAb) responses against several Variants of Concern (VOCs), including B.1.351/Beta, B.1.1.7/Alpha, P.1/Gamma, B.1.617.2/Delta and B.1.1.529/Omicron strains. The neutralizing antibody (NAb) response was robust with both primary vaccination strategies and tended to be higher for almost all VOCs following the heterologous prime-boost regimen.
引用
- Dubé C, Paris-Robidas S, Andreani G, et al. Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines. Vaccine. 2022. PMID: 35654621. doi:10.1016/j.vaccine.2022.05.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。